L Hansson1, D H Smith, R Reeves, P Lapuerta. 1. Division of Clinical Hypertension Research, Institute for Geriatrics, Uppsala Universitet, Sweden.
Abstract
BACKGROUND: Although it is generally acknowledged to be a problem in severe hypertension, headache has not been consistently associated with mild-to-moderate hypertension. PATIENTS AND METHODS: In 7 randomized, double-blind, placebo-controlled trials, which included 2,673 patients with mild-to-moderate hypertension (defined as seated diastolic blood pressure of 95-110 mm Hg), patients were randomized to receive once-daily treatment with irbesartan, an angiotensin II receptor blocker (n= 1,987), or placebo (n=686). The data were pooled and analyzed retrospectively to determine whether the level of hypertension was associated with headache and whether antihypertensive therapy reduced the incidence of headache. RESULTS: Factors found to be predictive of headache incidence were diastolic blood pressure, sex (female), and age (<50 years). In comparison with placebo, the use of irbesartan was associated with a significant reduction in the incidence of headache (P=.003). CONCLUSIONS: These data suggest that mild-to-moderate hypertension is not asymptomatic and that the incidence of headache can be reduced by antihypertensive treatment with a favorable adverse effect profile.
RCT Entities:
BACKGROUND: Although it is generally acknowledged to be a problem in severe hypertension, headache has not been consistently associated with mild-to-moderate hypertension. PATIENTS AND METHODS: In 7 randomized, double-blind, placebo-controlled trials, which included 2,673 patients with mild-to-moderate hypertension (defined as seated diastolic blood pressure of 95-110 mm Hg), patients were randomized to receive once-daily treatment with irbesartan, an angiotensin II receptor blocker (n= 1,987), or placebo (n=686). The data were pooled and analyzed retrospectively to determine whether the level of hypertension was associated with headache and whether antihypertensive therapy reduced the incidence of headache. RESULTS: Factors found to be predictive of headache incidence were diastolic blood pressure, sex (female), and age (<50 years). In comparison with placebo, the use of irbesartan was associated with a significant reduction in the incidence of headache (P=.003). CONCLUSIONS: These data suggest that mild-to-moderate hypertension is not asymptomatic and that the incidence of headache can be reduced by antihypertensive treatment with a favorable adverse effect profile.
Authors: M Prencipe; A R Casini; C Ferretti; M Santini; F Pezzella; N Scaldaferri; F Culasso Journal: J Neurol Neurosurg Psychiatry Date: 2001-03 Impact factor: 10.154
Authors: Joel M Neutel; Stanley S Franklin; Suzanne Oparil; Amitabha Bhaumik; Agata Ptaszynska; Pablo Lapuerta Journal: J Clin Hypertens (Greenwich) Date: 2006-12 Impact factor: 3.738
Authors: Joel M Neutel; William J Elliott; Joseph L Izzo; Chao L Chen; Harvey N Masonson Journal: J Clin Hypertens (Greenwich) Date: 2002 Sep-Oct Impact factor: 3.738